To the best of the authors′ knowledge, this study is the first systematic review and meta-analysis aiming to compare two long-acting GLP-1 receptor agonists, i.e. dulaglutide and liraglutide, which are prescribed to subjects with type 2 diabetes with or without other hypoglycemic drugs. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.